申请人:BANYU PHARMACEUTICAL CO., LTD.
公开号:EP2077266A1
公开(公告)日:2009-07-08
Provided are a compound of a formula (I) and its pharmaceutically-acceptable salt, which have a glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity.
[In the formula, R1 and R2 each independently represent a lower alkyl group; X1 represent a group of a formula (II-1):
(wherein R1 and R12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they are attached, R1 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH2)m, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3).]
本发明提供了一种式(I)化合物及其药学上可接受的盐,它们具有激活葡萄糖激酶的作用,因此可用于治疗糖尿病和肥胖症。
[式中,R1 和 R2 各自独立地代表一个低级烷基;X1 代表一个式(II-1)的基团:
(其中 R1 和 R12 各自独立地代表氢原子或低级烷基,或 R1 和 R12 与它们所连接的氮原子一起可形成 4 至 7 元含氮脂肪族环(构成 4 至 7 元含氮脂肪族环的一个碳原子可被氧原子取代),或 R11 和 R12 与(CH2)m 中的一个碳原子一起可形成 4 至 7 元含氮脂肪族环;m 表示 1 至 3 的整数)]。